Journal of Pharmacovigilance

OPEN ACCESS Freely available online

Hypothesis

An Idea of Using Drug Combination Therapy through Dissolving Micro-needles to Treat Streptozotocin-nicotinamide Induced Diabetic Rats

Mohd Yaqub Khan, Min-Hua Chen*

Biomedical Engineering Department, Small and Controlled Release Lab, Chung Yuan Christian University, Taiwan

ABSTRACT

Micro-needle transport approach has been used from past few a long time as a method to break the stratum corneum layer of skin and to perform the effective transport of drug across the skin and it is especially used for delivery of peptides, protein, DNA, oligonucleotides, molecular mass medicine and inactivated viruses across the dermal layer of the skin. In this hypothetical paper, we specifically targeted on how we will develop double-layer micro-needle which can deliver drug-mixture therapy efficaciously. Because there are many diseases together with cancer, tuberculosis, diabetes, leprosy, HIV, and AIDS, which may be efficiently handled by way of drug-combination therapy however this remedy is particularly confined to the tablet, capsule or another form of dosage. If we can develop double- layered micro-needles, can an opportunity to treat these illnesses with painless delivery. In the paper, we have tried to deal with type-2 diabetes with double-layered micro needle and that is formulated with the aid of hypothetically designed capsule which has the projection in it and which may be connected with projection of primary micro-needle and can form cone-like cavities and from these cavities we will deliver our drug and materials for the development of secondary layer on a primary layer of micro-needle and this technique can be utilized in different disease remedy and it is going to reduce fee of treatment, increase in patient compliance, site directed drug-delivery, increase in bioavailability of drug in the blood stream and increase in therapeutic index with less side effects.

Keywords: Micro-needles; Double-layer micro-needles; Type-2 diabetes; Hypothetically designed capsule; Therapeutic index

INTRODUCTION

From the past few decades, the employment of syringe injection for delivery of drug particularly for delivering anti-diabetic medicine has been magnificently magnified in variety. However, we've got some limitations related to the standard syringe, the chance of infection and inflammation at the location of injection related to pain and anxiety. Another additional disadvantage includes manufacturing waste, the value in production, safety protocol needed for disposal and alternative disease associated with the employment of unsterilized syringe over the amount [1]. In this constraint, we tend to encourage to use micro needles over the quality of syringe and thanks to micro-needle posses' bound blessings over standard syringes like: The administration of huge molecule is feasible, Painless administration, First-pass metabolism is avoided, Compared to hypodermic/ standard injection, the speed of healing at the injection web site is quicker, Ease of administration, Enhanced drug effectuality might cause dose reduction, Rapid drug delivery will be achieved by micro-needles plus associate degree electrically controlled micro-pump, The rate of drug delivery is additional manageable compared with drug delivery *via* the stratum [2]. Micro needles (MNs) are microscopic needles and size ranges from one to a hundred metric linear units and one micron in diameter and organized on a pad that's robust enough too specific into the skin and transports the drug across the skin. It's little to avoid nerve stimulation. These microstructure devices consist of microstructure projection coated with a drug or with a vaccinium and applied on the skin to supply intradermic delivery of the drug (Figure 1) [3].

MATERIALS AND METHODS

Types of Micro-needle

Based on the excellence, we are able to classify micro-needles as solid, hollow, coated, and dissolving micro needles (Figure 2) [4].

Solid micro-needles: These area unit a set of projections with arrays which will be used for making holes in corneum and area unit applied before the appliance of a drug and so removed.

***Correspondence to:** Chen MH, Small and Controlled Release Lab, Biomedical Engineering Department, Chung Yuan Christian University, Taiwan-32023, Tel: 979736802; E-mail: chen.minhua@cycu.edu.tw

Received: January 14, 2020; **Accepted:** March 03, 2020; **Published:** March 11, 2020

Citation: Khan MY, Chen MH (2020) An Idea of Using Drug Combination Therapy through Dissolving Micro-needles to Treat Streptozotocin-nicotinamide Induced Diabetic Rats. 8.279. doi-10.35248/2329-6887.20.8.279.

It applies these micro-needles for a precise amount and these will develop micro-channels within the skin to assist in transportation of the drug across the stratum layer [5, 6].

Coated micro-needles: These micro-needles are encircled by a drug dispersion layer or with a drug resolution. The number of drugs is loaded depends upon the thickness of the coating and also the size of micro-needles and these micro-needles is explored for delivery of the higher derma layer. High mass compounds like proteins, vaccines, and oligonucleotides are delivered by the assistance of those micro- needles [7].

Hollow micro-needles: These micro-needles contain a hollow bore within the middle. Hollow bore bypasses the horny layer of the skin and permits the medications to taste these hollow bores and reaches the opposite lower layers of the cuticle. These micro-needles area unit in the main utilized to move drug solutions directly into the skin layer by making an immediate channel for the drug to pass [8].

Dissolving micro-needles: These micro-needles get utterly dissolved within the skin and leave no residue behind it. These micro-needles usually form up of soluble materials like polymers and sugar that area unit inert, safe and can get utterly dissolve within the skin. Medication area unit incorporated within these micro-needles to urge free into the skin [9]. Dissolution and bio-acceptability of compound within the skin create it best for semi-permanent medical care with improved patient compliance. Whereas developing dissolving micro-needles, we must always pay a lot of specialise in the drug distribution across the needle. Thus, polymer-drug mixture may be an essential step whereas developing dissolving micro-needles [7].

Hydrogel-forming micro-needle: These micro-needles are the most recent development within the series of micro-needles [7]. The arrays of those micro-needles comprise super-swelling polymers. This chemical compound will take an oversized quantity of water into three-dimensional compound network as a result of this chemical compound is deliquescent [10]. These arrays absorb ECF when insertion into the skin and timely to make continuous channels between dermal capillary circulation and also the drug patch-reservoir resulting in the diffusion of the drug into the skin (Figure 3) [11].

Diabetes Mellitus

We could outline DM as a bunch of metabolic diseases that are characterised by symptoms thanks to defects of endocrine secretion and/or multiplied cellular resistance to endocrine [12]. Such deformities arise because of irregular functions of the regulative systems chargeable for the mobilization of metabolic fuels and storage of it, which incorporates the organic process and catabolism of lipids, carbohydrates, and proteins, emanating from the defective hormone secretion, hormone action, or both [13]. We can classify diabetes into 2 varieties i.e. insulin- dependent diabetes (IDDM, kind I) and ketoacidosis-resistant diabetes mellitus (NIDDM, Type II). The kind I polygenic disorder is an associate degree autoimmune disorder that's characterised by an area inflammatory reaction in and around cells of the isle and later ends up in the destruction of insulin-secreting cells. Whereas in kind II polygenic disorders characterized by peripheral endocrine resistance and impairment of endocrine secretion [14]. Chronic and different metabolic disturbances of DM might cause long- run tissue and organ injury [12] and alternative complications like vessel diseases, peripheral tube illness, kidney failure, neuropathy,



Figure 1: Graphical representation.



Figure 2: (a) Basic Structure of Microneedle (b) Microneedle mould (c) Bright field micrographs of dissolving Microneedle (d) SEM image of Microneedle.

stroke, retinopathy, blindness, and amputations, etc. [14]. Drugs are available to treat type-II diabetes such as sulfonylurea (glyburide, glimepiride, glipizide), metformin, alpha-glucosidase inhibitor (acarbose, miglitol, voglibose), thiazolidinedione (pioglitazone, rosiglitazone) (Figure 4) [15]. Drug combination medical aid has bound benefits over mono-drug medical aid like two medications, every drug functioning at a separate site, block different effector pathways; thus, once two drug categories are co-administered, then there'll be increased lowering result of blood pressure. Drug combination medical aid might increase effectiveness by counteracting counter-regulatory mechanisms of one drug that's triggered by the opposite drug. Combination medical aid has fewer adverse effects as compared to high-dose mono-therapy that results in increasing patient compliance and preventing treatment failure which may result from mono-therapy. Together medical aid, adverse effects of one drug are effectively neutralized by another drug [16].

Hypothesis

Drugs to be used in drug-combination therapy: Normally in oral preparation (tablets), we tend to want to offer glipizide and metformin in 2.5 mg and 250 mg severally together medical care. We are going to use a similar quantitative relation of 1:100 for developing our micro-needles for our first-line medical care (Figure 5) [17].

Preparation of double-layered micro-needles: We are exploitation our base material for developing micro-needle is Hyaluronan (HA) (sodium hyaluronate, average Mw 150 kD which might be purchased from Life core Biomedical), a collection of mould for formation of micro-needle during which there's one special style mould, and our medication which is able to be employed in combination medical care in a very totally different proportion to see it best result (glipizide and metformin) (Table 1 and Figure 6) [18].

- We have used our primary dissolving micro-needle as our base for the event of double-layer dissolving micro-needles.
- Now we've got opened our theoretic capsule in 2 components, one half having projection which is able to be fastened with our basic primary dissolving micro-needle and permit to develop cavities higher than primary micro-needle. Gap that is found higher than the opening of cavities from their medication and micro-needle forming material is passed with high pressure and speed through an inlet. With the assistance of pressure and speed of fabric flow, we will manage



Figure 3: Different types of micro-needles on skin layer.



Figure 4: Comparison between healthy, type I & type II diabetes mellitus.



Figure 5: **(a)** Primary mould used to form first-layer micro-needle **(b)** Hypothetical-design capsule for developing double-layer micro-needles.

Table 1: Overview of the different formulation composition used to prepare the double-layered dissolving micro-needles. The compositions refer to the liquid formulations before double-layered dissolving micro-needles.

Formulation	Layer	Composition	Formulation approach	Layer	Composition	Formulation approach
A	First	Metformin/Hyaluronan (% w/v)	24.75 mg/50 ml	Second	Glipizide/Hyaluronan (% w/v)	0.25 mg/50 ml
B	First	Metformin/Hyaluronan (% w/v)	49.50 mg/50 ml	Second	Glipizide/Hyaluronan (% w/v)	0.50 mg/50 ml
C	First	Metformin/Hyaluronan (% w/v)	69.30 mg/50 ml	Second	Glipizide/Hyaluronan (% w/v)	0.70 mg/50 ml
D	First	Metformin/Hyaluronan (% w/v)	99.0 mg/50 ml	Second	Glipizide/Hyaluronan (% w/v)	1.00 mg/50 ml
Control	First	Metformin/Hyaluronan (% w/v)	0.00 mg/50 ml	Second	Glipizide/Hyaluronan (% w/v)	0.00 mg/50 ml



Figure 6: Preparation of single layer dissolving micro-needle.

the speed of formation of secondary layer on the first layer. We will fix the second part of a capsule having a holding plate that's accountable to connect our primary micro-needle structure in position and with a projection of the primary layer and making a lock condition.

- After the developing micro-needle, leave the micro-needle within the capsule for night long at 37°C to dry and once waterlessness then takes away micro-needle from the array.
- Now repeat the first layer and second layer process development method for developing the different variation of metformin and glipizide double layer micro-needles (Figure 7).

RESULTS AND DISCUSSION

Testing of hypothesis

Induction of experminental diabetes in Wistar rats: Rats were unbroken in a very controlled temperature and lightweight condition (i.e. 37°C and 12:12 hour light: dark cycles) [19] and permit free access to water and food more or less for two weeks to adopt the experimental conditions. Rats were fasted for twelve hours to avoid failure of induction and to avoid aldohexose competition with streptozotocin at GLUT2 transporters. Through an experiment, we are able to induce polygenic disorder in rat by giving the only dose of streptozotocin through intraperitoneal route (i.e. sixty-five mg/kg weight of streptozotocin dissolved in a very 0.1 M freshly ready change state buffer having pH 4.5), once the quarter-hour we'll provide the second dose of nicotinamide (120 mg/kg body weight) and dissolved in traditional saline. To counter drug-induced hypoglycaemia, rats got a five-hitter aldohexose resolution long. Blood samples were collected once seventy- two hours of induction from the tail vein of rats by a puncture to work out the glucose with a glucometer. If the glucose level is over 250 mg/dl, then polygenic disorder is confirmed and currently we tend to check our different quantitative relation of metformin and glipizide double-layer

micro-needles on diabetic rats (Figure 8) [20].

Implication of hypothesis

After, the made development of double-layered micro-needle that is comprised of metformin and glipizide and separated by two layers of hyaluronan. During this paper, we've hypothetic tried to make double-layered micro-needles by the assistance of hypothetically designed capsule which might be worked on a basis of lock and key theory as a result of its own projection which might be fitted adjacently to micro-needle projection of primary micro-needle or we are able to say single layer micro-needle and by this technique, it permits to developed cup-like cavities on top of the primary or single layer micro-needle. From these cup-like cavities our drug and material will simply flow with the assistance of a hole that is give non top of the cavities and by the assistance of an inlet, we are able to simply monitor and manage the speed of drug and material and, it helps us in developing the second layer on primary layer in a very controlled manner (Figure 9) [21]. We tend to create the various formulations of metformin and glipizide through variation in their formulation unit and we have hypothetically given procedure for testing on Wistar rat, once causing polygenic disease to Wistar rat through intraperitoneal route by injecting streptozotocin and nicotinamide combination. Once testing each formulation on Wistar rat we are able to check the aldohexose level by glucometer and that we can compare the results of each formulation and we are able to calculate serum



Figure 7: Preparation of double layer dissolving micro-needle.

Figure 8: (a) Wistar Rat (approxiamtely 150-200 g for experiment) (b) Hair removed by clipper and hair removal cream for insertion microneedles into diabetes induced wistar rat (c) Insertion of double-layer microneedle for treatment of type-2 diabetic wistar rat.



Figure 9: Cytotoxic aand protective action of streptozotocin & nicotinamide on B-cells respectively. High nicotinamide intake could result in a rise within the production of reactive element species and result in aerophilous stress and hypoglycaemic agent resistance.



Figure 10: Mechanism of action of metformin & glipizide through double-layered micro-needle.

level of total cholesterol, glyceride, and high- density lipoprotein-cholesterol by collection of blood sample from tail vein of every Wistar rat and that we will study microscopic anatomy of normal, diabetic and drug-treated exocrine gland of Wistar rat (Figure 10) [22].

CONCLUSION

In summary, until we've got a single-layer micro-needle nearly for each un-wellness however still, it's a dream to use an inspiration of drug combination medical aid in micro-needle to treat diseases like polygenic disorder, T.B., cancer, malaria, leprosy, and HIV/AIDS, rather than the pill, capsule or the other indefinite quantity forms. Size of the micro-needle may be a gift for humans owing to its size we will get painless treatment however this size is additionally a limitation for developing the second layer on the first layer of the micro-needle. Double-layer micro-needle can face a retardant owing to its size, form and double layer, the realm can become slim to carry the drug within and it'll become tough to deliver the additional quantity of the drug to a patient and that we will improve the indefinite quantity by increasing the number of applications of the micro-needle to a patient. Within the future maybe it'll do to develop this kind of micro-needle and it'll facilitate patients and in addition, doctor to induce additional precise and site-targeted delivery of drug and by the help of double-layer micro-needle, we'll scale back price, medical specialty waste, and improve patient compliance.

COMPETING INTERESTS

The authors declare that they have no competing interest.

ACKNOWLEDGEMENTS

This study was financially supported by Ministry of Science and Technology, Taiwan (Grant No.: MOST 108-2218-E-033-005-MY2)

REFERENCES

1. Agrawal L, Vimal SK, Chen MH, Shiga T. An Idea of Using Microneedles for the Targeted Drug Delivery to Overcome the Blood Brain Barrier for the Treatment of Brain Diseases. J Pharmacovigil. 2018;6:1-4.
2. Bariya SH, Gohel MC, Mehta TA, Sharma OP. Microneedles: an emerging transdermal drug delivery system. J Pharm Pharmacol. 2012;64:11-29.
3. Ravi G, Gupta VN, Gowrav MP. A Comprehensive Review on Microneedles - an Archetype Swing in Transdermal Drug DeliverY. Indo American Journal of Pharmaceutical Research. 2017;7:7399-7416.
4. Hsiao MH, Ye HF, Liu TJ, Wang J. Drug Loading on Microneedles. Advances in Chemical Engineering and Science. 2019;9:204-222.
5. Kumar SH, Singh V. Nanoemulsification-a novel targeted drug delivery tool. Journal of Drug Delivery and Therapeutics. 2012;2:40-45.
6. Morrow DI, McCarron PA, Woolfson AD, Donnelly RF. Innovative strategies for enhancing topical and transdermal drug delivery. The Open Drug Delivery Journal. 2007;1:36-59.
7. Waghule T, Singhvi G, Dubey SK, Pandey MM, Gupta G, Singh M, et al. Microneedles: A smart approach and increasing potential for transdermal drug delivery system. Biomed Pharmacother. 2019;109:1249-1258.
8. Akhtar N. Microneedles: An innovative approach to transdermal delivery—A review. Int J Pharm Pharm Sci. 2014;6:18-25.
9. Nayak S, Suryawanshi S, Bhaskar V. Microneedle technology for transdermal drug delivery: applications and combination with other enhancing techniques. Journal of Drug Delivery and Therapeutics. 2016;6:65-83.
10. Donnelly RF, Singh TR, Alkilani AZ, McCrudden MT, O'Neill S, O'Mahony C, et al. Hydrogel-forming microneedle arrays exhibit antimicrobial properties: potential for enhanced patient safety. Int J Pharm. 2013;451:76-91.

11. Donnelly RF, Singh TR, Garland MJ, Migalska K, Majithiya R, McCrudden CM, et al. Hydrogel-forming microneedle arrays for enhanced transdermal drug delivery. Adv Funct Mater. 2012;22:4879-4890.

12. Harikumar K, Kumar BK, Hemalatha GJ, Kumar MB, Lado SF. A review on diabetes mellitus. International Journal of Novel Trends in Pharmaceutical Sciences. 2015;5:201-217.

13. Piero MN, Nzaro GM, Njagi JM. Diabetes mellitus-a devastating metabolic disorder. Asian Journal of Biomedical and Pharmaceutical Sciences. 2015;5:1-7.

14. Deshmukh CD, Jain A. Diabetes Mellitus: A Review. Int J Pure Appl Biosci. 2015;**3**:224-230.

15. Tripathi S, Saroj BK, Khan MY. Pharmacological Evaluation of Folk Medicinally used Plant by usin Streptozotocin Induced Rat Models. Asian Journal of Pharmacy and Technology. 2018;8:231-243.

16. Neutel J. Advantages of Combination Therapy Compared with Monotherapy. InCombination Therapy in Hypertension. Springer Healthcare, Tarporley. 2011;23-35.

17. Sharma R, Gupta R, Jhat RK. Development and evaluation of sustained release bilayer matrix tablet of glipizide and metformin hydro chloride. Int J Drug Res Technol. 2013;3:60-66.

18. Leone M, Priester MI, Romeijn S, Nejadnik MR, Mönkäre J, O'Mahony C, et al. Hyaluronan-based dissolving microneedles with high antigen content for intradermal vaccination: Formulation, physicochemical characterization and immunogenicity assessment. Eur J Pharm Biopharm. 2019;134:49-59.

19. Husni A, Purwanti D. Blood glucose level and lipid profile of streptozotocin-induced diabetes rats treated with sodium alginate from Sargassum crassifolium. Journal of Biological Sciences. 2016;16:58.

20. Elamin NM, Fadlalla IM, Omer SA, Ibrahim HA. Histopathological Alteration in STZ-Nicotinamide Diabetic Rats, a Complication of Diabetes or a Toxicity of STZ. Int J Diabetes Clin Res. 2018;5:91.

21. Szkudelski T. Streptozotocin–nicotinamide-induced diabetes in the rat. Characteristics of the experimental model. Exp Biol Med. 2012;237:481-490.

22. Hendriks AM, Schrijnders D, Kleefstra N, de Vries EG, Bilo HJ, Jalving M, et al. Sulfonylurea derivatives and cancer, friend or foe?. Eur J Pharmacol. 2019:172598.